Selected References:
- Abraham K, 2021. Maternal and Perinatal Outcomes of Influenza in Pregnancy after Treatment with Oseltamivir. J Glob Infect Dis. 13(1):20-26.
- American College of Obstetricians and Gynecologists (ACOG). 2018. Committee Opinion No. 753: Assessment and treatment of pregnant women with suspected or confirmed influenza. Obstet Gyn, 132(4):e169-e173.
- Antiviral drugs for influenza for 2023-2024. 2023. Med Lett Drugs Ther. 65(1689):177-182.
- Aoki FY, et al. 2013. The use of antiviral drugs for influenza: A foundation document for practitioners. Can J Infect Dis Med Microbiol, 24(Suppl C):1-15.
- Beau A-B, et al. 2014. Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database. BJOG, 121(7):895-900.
- Centers for Disease Control and Prevention. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza. MMWR, 60(No. RR-1):1-25.
- Chambers CD, et al, OTIS Collaborative Research Group. 2019. Oseltamivir use in pregnancy: Risk of birth defects, preterm delivery, and small for gestational age infants. Birth Defects Res, 111(19):1487-1493.
- Chow EJ, et al. Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy. Open Forum Infect Dis. 8(6):ofab138.
- Cizeron A, et al. 2021. Low rate of oseltamivir prescription among adults and children with confirmed influenza illness in France during the 2018-19 influenza season. J Antimicrob Chemother. 76(4):1057-1062.
- Dunstan H, et al. 2014. Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study. BJOG, 121(7):901-906.
- Fodor E, et al. 2023. An Observational Study on the Pharmacokinetics of Oseltamivir in Lactating Influenza Patients. Clin Pharmacol Ther doi:10.1002/cpt.3107.
- Graner S, et al. 2017. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ, 356:j629.
- Greer LG, et al. 2010. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. Obstet Gynecol, 115(4):711-716.
- Greer LG, et al. 2011. Pharmacokinetics of oseltamivir in breast milk and maternal plasma. Am J Obstet Gynecol, 204: 524.e1-4.
- Laibl VR and Sheffield JS. 2005. Influenza and pneumonia in pregnancy. Clinics in Perinatology, 32:727-738.
- Lian J, et al. 2022. Neonatal outcomes after neuraminidase inhibitor use during pregnancy: A meta-analysis of cohort studies. Br J Clin Pharmacol. 88(3):911-918.
- Mancilla-Galindo J, et al. 2021. All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study. EXCLI J. 20:199-222.
- Saito S, et al. 2013. Outcomes of infants exposed to oseltamivir or zanamivir in utero during pandemic (H1N1) 2009. Am J Obstet Gynecol, 209 (2): 130.e1-9.
- Siston A, et al. 2010. Pandemic 2009 influenza A (H1N1) virus illness among pregnant women in the United States. JAMA, 3030(15):1517-1525.
- Svensson T, et al. 2011. Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy. Pharmacoepidemiol Drug Saf, 20(10): 1030-1034.
- Tanaka T, et al. 2009. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ, 181(1-2):55-58.
- Van Bennekom CM, Kerr SM, Mitchell AA. 2019. Oseltamivir exposure in pregnancy and the risk of specific birth defects. Birth Defects Res, 111(19):1479-1486.
- Wentges-van Holthe N, et al. 2008. Oseltamivir and breastfeeding. Int J Infect Dis, 12:451.
- Wollenhaupt M, et al. 2014. The safety of oseltamivir in pregnancy: an updated review of post-marketing data. Pharmacoepidemiol Drug Saf, 23(10):1035-1042.
- Xie H-Y, et al. 2013. Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic. Am J Obstet Gynecol, 208:293.e1-7.
